The efficacy and safety of a new tumor necrosis factor inhibitor, certolizumab pegol, in active rheumatoid arthritis has now been assessed in three phase III, multicenter, randomized, double-blind, ...
Certolizumab pegol is distinct from other TNFi in terms of its structure. It is composed of the antibody binding fragment (Fab) of humanized monoclonal antibody against TNF conjugated to polyethylene ...
In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not ...
- New Cimzia® data, with sites in the US, demonstrate safety and efficacy, increased participation in social activities for adult RA patients ATLANTA, June 16 ...
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who received abatacept or certolizumab pegol were more likely to achieve ...
Please provide your email address to receive an email when new articles are posted on . Patients dosed with certolizumab pegol for moderate to severe plaque psoriasis achieved and maintained absolute ...
The IMprove Pregnancy in APS with Certolizumab Therapy (IMPACT) clinical trial, supported by the Lupus Foundation of America through a three-year grant, found that certolizumab pegol, a medication ...
the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to ...
The Food and Drug Administration (FDA) has approved Cimzia to treat certain inflammatory conditions in adults, including rheumatoid arthritis. It’s also FDA approved for polyarticular juvenile ...
The frequency of primary and secondary nonresponse has contributed to the perceived need for new agents. Thus there has been the development of a number of other biologic agents for use in RA ...
The appraisal committee (section 6) considered evidence submitted by UCB Pharma and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback